Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation

Increased utilization of hepatitis C virus (HCV)-positive liver allografts for liver transplant (LT) has been endorsed as one of several ways to combat national organ shortages. However, HCV-positive donors remain poorly characterized, and Organ Procurement and Transplantation Network regional diffe...

Full description

Saved in:
Bibliographic Details
Published in:JAMA network open 2020-12, Vol.3 (12), p.e2027551-e2027551
Main Authors: Da, Ben L, Ezaz, Ghideon, Kushner, Tatyana, Crismale, James, Kakked, Gaurav, Gurakar, Ahmet, Dieterich, Douglas, Schiano, Thomas D, Saberi, Behnam
Format: Article
Language:English
Subjects:
Adult
Allografts - supply & distribution
Allografts - virology
Cross-Sectional Studies
Female
Gastroenterology and Hepatology
Hepacivirus
Hepatitis C
Hepatitis C Antibodies - blood
Humans
Liver
Liver - virology
Liver Transplantation - statistics & numerical data
Liver transplants
Male
Middle Aged
Online Only
Original Investigation
Regional differences
Regions
Tissue and Organ Procurement - statistics & numerical data
Tissue Donors - statistics & numerical data
Tissue Donors - supply & distribution
Transplants & implants
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increased utilization of hepatitis C virus (HCV)-positive liver allografts for liver transplant (LT) has been endorsed as one of several ways to combat national organ shortages. However, HCV-positive donors remain poorly characterized, and Organ Procurement and Transplantation Network regional differences in the utilization of HCV-positive liver allografts are unclear. To characterize HCV-positive donors and the allografts that come from them. In this cross-sectional study, the Scientific Registry of Transplant Recipients database was queried for all donors who underwent HCV testing from June 2015 to December 2018. Clinical and allograft characteristics were evaluated, and utilization across the United States was studied. Patients with positive or negative results for HCV antibody (Ab) and HCV nucleic acid amplification testing (NAT) were included in this study. Donors utilized for living donor transplant and pediatric (age
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2020.27551